Medtronic and Kimberly-Clark are Dividend Aristocrats trading well below historical valuations, offering compelling buy-the-dip opportunities. MDT has strong revenue growth, a robust innovation pipeline, and a 3.3% yield, with a forward P/E of 15.4 versus its historical 17.5. KMB is executing on transformation and innovation, with margin gains, a 5.2% yield, and a forward P/E of 13.0, far below its historical 17.7.